|
1/2026
vol. 22
Original paper
Guideline-directed medical therapy in Polish patients with chronic coronary syndrome and advanced chronic kidney disease: insights from the ISCHEMIA-CKD trial
Edyta Kaczmarska-Dyrda
1
,
- Coronary and Structural Heart Diseases Department, National Institute of Cardiology, Warsaw, Poland
- Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York, USA
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
- Department of Cardiology, Medical University of Lodz, Poland
- Department of Internal Medicine and Cardiology, Medical University of Warsaw, Poland
- Nephrology Department, Międzyleski Szpital Specjalistyczny, Warsaw, Poland
- First Department of Internal Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland
- National Institute of Cardiology, Warsaw, Poland
Adv Interv Cardiol 2026; 22, 1 (83): 1–7
Online publish date: 2026/03/09
Get citation
1. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81. 2.
Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006; 70: 2021-30. 3.
Bangalore S, Maron DJ, O’Brien SM, et al. Management of coronary disease in patients with advanced kidney disease. N Engl J Med 2020; 382: 1608-18. 4.
Pracoń R, Demkow M, Anthopolos R, et al. Optimal medical therapy in patients with stable coronary artery disease in Poland: the ISCHEMIA trial experience. Pol Arch Intern Med 2021; 131: 16100. 5.
Bangalore S, Maron DJ, Fleg JL, et al. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): rationale and design. Am Heart J 2018; 205: 42-52. 6.
Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305. 7.
Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303-9. 8.
Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48. 9.
Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-407. 10.
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92. 11.
Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-16. 12.
Cheung AK, Chang TI, Cushman WC, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021; 99: S1-87. 13.
Qiao Y, Shin JI, Chen TK, et al. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med 2020; 180: 718-26.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License ( http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
|
